Lexaria Bioscience (LEXX) has released an update.
Lexaria Bioscience is set to explore a new frontier with its DehydraTECH-liraglutide, an oral version of the multi-billion dollar drug liraglutide, following promising results in animal studies. The company plans a human pilot study to compare its formulation against the injectable Saxenda® and aims to unlock potential revenue opportunities in the GLP-1 drug market. If successful, this could lead to further trials and expansion within this lucrative sector.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- ‘Keep on Buying’: Bank of America Weighs In on Nvidia Stock Ahead of Earnings
- “Be the Leader You’ve Been Complaining For!” Paramount Stock (NASDAQ:PARA) Dips as Paramount Pulls Out of Politics
- Don’t “Get Rid of All Your Engine Designers”: Ford Stock (NYSE:F) Dips as it Brings Back a Big Name in Internal Combustion